ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "B-Lymphocyte"

  • Abstract Number: 0029 • ACR Convergence 2025

    A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing

    Joao Carlos Batista-Liz1, María Sebastián Mora-Gil2, Evan Troendle3, Oisin Cappa3, Maite Leonardo4, Ana Peñalba4, Luis mARTIN pENAGOS5, Ligia Gabrie-Rodriguez6, Rafael Gálvez Sánchez6, Jose Luis Callejas7, Belen Sevilla8, Diego de Argila9, Esther Vicente-Rabaneda9, Santos Castañeda10, David Simpson3, Ricardo Blanco11, Verónica Pulito Cueto1 and Raquel Lopez Mejias1, 1IDIVAL, Santander, Spain, 2Immunopathology Group, IDIVAL, Santander, Spain, 3Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, 4Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 7Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, 8Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 9Hospital Universitario de la Princesa, Madrid, Spain, 10Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 11Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined…
  • Abstract Number: 1172 • ACR Convergence 2025

    A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease

    Matthew Charles Baker1, Audra Horomanski2, Robert Fairchild3, Yuhan Liu3, Mariani Diaz Deluna3, Tobias Lanz4, Saurabh Gawde3, Mehdi Khalighi3, Benjamin Franc3, Mrudula Penta3, Nancy Pham3 and Kip Guja3, 1Stanford University, Menlo Park, CA, 2Stanford University, Palo Alto, CA, 3Stanford University, Stanford, CA, 4Stanford University, Stanford

    Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic, systemic, immune-mediated disease that is commonly treated with B cell depletion. However, due to potential risks associated with…
  • Abstract Number: 2695 • ACR Convergence 2025

    B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents

    Carlo Tur1, Markus Eckstein2, Laura Bucci1, Janina Auth3, Christina Bergmann1, Simon Rauber4, Melanie Hagen1, Danae-Mona Nöthling1, Sebastian Böltz1, Andreas Wirsching1, Filippo Fagni5, Giulia Corte6, Panagiotis Garantziotis1, Jule Taubmann7, jochen wacker1, Andreas Ramming8, Maria Antonietta D'Agostino9, Arndt Hartmann10, Fabian Müller11, Andreas Mackensen12, Ricardo Grieshaber-Bouyer13, Georg Schett14, Aline Bozec1 and Maria Gabriella Raimondo1, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 2Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 4Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, 5Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, 6- Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 7Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 8Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, 9Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 10Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 11University Hospital of Erlangen, Erlangen, Germany, 12Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, 13University Hospital Erlangen, Erlangen, Germany, 14Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany

    Background/Purpose: Advanced protein-based therapies targeting B-cells, including glycoengineered CD20 monoclonal antibody obinutuzumab (OBI) and the CD19/CD3 T-cell engager blinatumumab (BLI), show promise for managing severe…
  • Abstract Number: 1096 • ACR Convergence 2025

    Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.

    Elisabet Perea1, Antonio Avilés2, Cristina RodrÍguez-Alvear3, Paloma Vela2, Vega Jovaní4, Agustín Martínez2, M.Pilar Bernabeu Gonzalvez2, Irene Calabuig2, Ana Lucia Jiménez-Portillo5, Alejandra Bermúdez2, Silvia Gomez-Sabater2, Rocío Caño2, Francisco Marco5 and Mariano Andrés6, 1Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain, Alicante, Spain, 2Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, 3Virgen de la Peña General Hospital, Fuerteventura, Spain, 4Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, 5Immunology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, 6Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain

    Background/Purpose: Interleukin-6 (IL-6) is a proinflammatory cytokine involved in B cell differentiation and antibody production through the JAK/STAT pathway. In clinical practice, hypogammaglobulinemia (HGG) has…
  • Abstract Number: 2439 • ACR Convergence 2025

    Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis

    Ahmad Alomari1, Nikita Shah2, Miguel Rodriguez3 and Diala Alawneh4, 1UCF- North Florida hospital, Gainesville, FL, 2UCF/HCA Florida North Florida Hospital, Gainesville, FL, 3SIMED Rheumatology, Gainesville, FL, 4University of Florida, Gainesville, FL

    Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), often leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).…
  • Abstract Number: 1003 • ACR Convergence 2025

    Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology 

    Yan Zhang1, Brittany Ross1, Aditi Upadhye1, Diana Galvan1, Shaun E Grosskurth1, Yanjie Bao1, Romina Riener1, Annabel Wang1, Aric Frantz1, Gregor B Adams1, Michael Rosenzweig1, Ramin Farzaneh-Far1, Priya Karmali1, Adrian I Bot1, Carl June2 and Haig Aghajanian1, 1Capstan Therapeutics, San Diego, CA, 2University of Pennsylvania, Philadelphia, PA

    Background/Purpose: A major objective in autoimmunity is immune reset, requiring autoreactive B cell depletion in tissues. We designed an in vivo CAR product candidate (CPTX2309)…
  • Abstract Number: 2421 • ACR Convergence 2025

    Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria

    Nicholas Bauer1, Philip Carlucci2, Rufei Lu1, Carla Guthridge1, Tayte Stephens3, Benjamin Jones4, Wade DeJager5, Susan Macwana1, Andrea Fava6, Sanchit Sanyal7, Erin Carter8, Mala Masson9, Jennifer Anolik10, Jennifer Barnas11, Peter Izmirly12, H Michael Belmont13, Kelly Ruggles14, Study Team ALE06 Clinical1, Brad Rovin15, Jill Buyon16, Michelle Petri17, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2New York University School of Medicine, New York, NY, 3University of Oklahoma Health Science Center, Oklahoma City, OK, 4Oklahoma State University, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Johns Hopkins University, Baltimore, MD, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8New York University Grossman School of Medicine, New York, NY, 9NYU Langone Medical Center- Division of Rheumatology, New York, NY, 10University of Rochester Medical Center, Rochester, NY, 11University of Rochester, Rochester, NY, 12New York University Grossman School of Medicine, New York, NY, 13NYU School of Medicine, New York, NY, 14NYU Grossman School of Medicine, Brooklyn, NY, 15The Ohio State University, Columbus, OH, 16NYU Grossman School of Medicine, New York, NY, 17Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Autoreactive B cell populations play a key role in the pathogenesis of lupus nephritis (LN). Therefore, it is hypothesized that dysregulation in the B…
  • Abstract Number: 0991 • ACR Convergence 2025

    MTHFD2 is a Novel Metabolic Target in Autoimmune Disease

    Laura McMillan, Celia Evans, Marina Makrecka-Kuka, Niamh Richmond, Gareth Davies, Hamel Patel, Michael Herdman, Mark Whitmarsh, Alessandro Mazzacani, Peter Bunyard, Madduri Ravin Rao and Iain Kilty, Sitryx Therapeutics, Oxford, United Kingdom

    Background/Purpose: Aberrant activation and persistence of adaptive immune responses play a central role in autoimmune pathogenesis. Where traditional immunosuppressive therapies offer a broad targeting approach,…
  • Abstract Number: 2048 • ACR Convergence 2025

    DDR2 auto-phosphorylation in patients with Warburg-Cinotti syndrome promotes differentiation of fibroblasts into myofibroblasts and expansion of immature B cells with antibody production.

    Sang Jin LEE and Yun Jeong Lee, Kyungpook National University School of Medicine, Daegu, Republic of Korea

    Background/Purpose: Warburg-Cinotti syndrome (WCS) is a rare connective tissue disorder caused by activating mutations in the DDR2 gene, characterized by progressive corneal neovascularization, keloid-like plaques,…
  • Abstract Number: 0982 • ACR Convergence 2025

    Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases

    cristiana Sieiro1, Juan García Herrero2, Jose Ordas Martínez3, Carolina Álvarez Castro3, Alejandra López Robles3, Ronald Colindres3, Ana María Sahagún4 and Jose María Ruiz de Morales3, 1Univrsity of Manchester, Manchester, United Kingdom, 2complejo asistencial universitario de leon, León, Spain, 3Complejo Asistencial Universitario de León, León, Spain, 4University of Leon, León, Spain

    Background/Purpose: Herpes zoster (HZ) is a common infection, particularly in older adults and women, and can lead to complications like neuropathic pain. The risk is…
  • Abstract Number: 1838 • ACR Convergence 2025

    Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE

    Lars Van Vliet, Annemarie Dorjée, René Toes and Jolien Suurmond, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Anti-dsDNA IgG antibodies are a hallmark of systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic inflammation and multi-organ damage. Evidence suggests that…
  • Abstract Number: 0941 • ACR Convergence 2025

    In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases

    Juliet Crabtree, Thomas Lee, David Soto, Prapti Vyas, Akinola Emmanuel, Matthew Theisen, Karolina Kosakowska, Maja Sedic, Rajat Das, Muthusamy Jayaraman, Megan Hoban, Joe Bolen and Isin Dalkilic-Liddle, Orna Therapeutics, watertown, MA

    Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and…
  • Abstract Number: 1836 • ACR Convergence 2025

    Emerging Role of B Cell Subtype-Specific Intracytoplasmic Toll-Like Receptor Expression and Serum Eotaxin as Biomarkers in Lupus Nephritis

    Jennifer Tiaré Balderas Miranda1, Yatzil Reyna Juárez2, Beatriz Alcalá-Carmona3, Nancy R Mejía Domínguez4, María José Ostos Prado3, José Luis Maravillas-Montero5, Fabiola Cassiano-Quezada6, Guillermo Juárez Vega4, karina santana7, Jiram Torres Ruiz8 and Diana Gómez-Martín9, 1Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 2Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, 3Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 4Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Tlalpan, Distrito Federal, Mexico, 6Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 7INCMNSZ, Ciudad de México, Federal District, Mexico, 8INCMNSZ, Mexico, Federal District, Mexico, 9INCMNSZ, Mexico city, Federal District, Mexico

    Background/Purpose: B cells play an essential role in lupus nephritis (LN) pathogenesis. However, abnormalities in specific subtypes like age-associated B cells (ABCs) and double negative…
  • Abstract Number: 0934 • ACR Convergence 2025

    The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis

    Arielle Glatman Zaretsky1, Carley Tasker1, Pablo Abreu1, Ciara Torres2, Li-Hong Ben1, Scott MacDonnell1, Andre Limnander1 and Jamie Orengo1, 1Regeneron, Tarrytown, NY, 2Regeneron, Tarrytown

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease with a prevalence of 1.4-15.13/100,000 adults globally. SLE is highly heterogenous and can involve…
  • Abstract Number: 1773 • ACR Convergence 2025

    Redefining disease activity assessment in IgG4-Related Disease: The role of classical and novel biomarkers

    Marta López1, rafeal Benito-Melero2, Laura Martinez-Martinez3, Hye Sang-Park4, sara Calleja3, Helena Codes Mendez5, Mar Concepción Martín3, Berta Magallares3, Ivan Castellví6, Ana Laiz5, Cesar Diaz3 and Hector Corominas7, 1Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, 2MD, barcelona, Spain, 3Hospital Santa Creu i Sant Pau, Barcelona, Spain, 4Hospital Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 5Sant Pau Hospital, Barcelona, Spain, 6Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, 7Hospital de Sant Pau, Barcelona, Spain

    Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disorder characterized by elevated serum IgG4 levels and tissue infiltration by IgG4-positive plasma cells. Despite advances in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology